Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
3 Stocks That Can Help You to Get Richer in 2025 and Beyond
These are three solid contenders for your portfolio. 
Via The Motley Fool
The Savvy Investor’s Cheat Sheet: 3 Deep Value Picks for May 2024
There are a few potentialy deep value stocks to buy that investors may wish to put on their watchlists by summer. 
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: May 2024
These biotech giants offer investors the best opportunity money can buy for excellent profits and returns this year. 
Via InvestorPlace
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Pfizer's Path To Profit: A Look At PFE Stock As Drugmaker Rolls Out $1.5B In Cost Reductions
Pfizer launched a $1.5 billion cost reduction program to enhance operational efficiencies and cut costs amid declining sales. Stock shows bullish momentum. 
Via Benzinga
Market Whales and Their Recent Bets on PFE Options
Via Benzinga
1 Top Dividend Stock to Load Up On Now
This deeply undervalued pharma stock is a top buy. 
Via The Motley Fool
Pfizer Unusual Options Activity
Via Benzinga
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Pfizer Initiates Multi-Year Cost Reduction Plan Targeting $1.5B Savings By 2027
The company disclosed the new program in a filing with the Securities and Exchange Commission. 
Via Benzinga
Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb
Experts predict a small rise in COVID-19 cases as a newly dominant strain spreads. The new strain, KP.2, represents 28% of Covid infections in the U.S. and experts believe its mutations have made the... 
Via Benzinga
Exposures COVID-19
7 Safe-Haven Stocks to Weather Any Storm
Explore top safe-haven stocks to buy now for stability and consistent growth during economic turbulence and uncertainty. 
Via InvestorPlace
3 Healthcare Stocks to Buy Now: May 2024
Healthcare stocks can perform well during times of heightened inflation and economic uncertainty. These are three to buy today. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
GSK Concealed Risk Associated With Discontinued Heart Burn Drug Zantac, Whistleblower Lawsuit Claims
Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. This follows Valisure's 2019 tests showing Zantac forms a carcinogen,... 
Via Benzinga
Topics Lawsuit Whistleblower
Exposures Financial Legal
3 Blue-Chip Stocks to Buy on the Dip: May 2024
The economy is going to preform well and you need to invest. These are the three blue-chip stocks to buy on the dip before they skyrocket. 
Via InvestorPlace
Topics Economy
Exposures Economy
Billionaires Are Buying Beaten-Down Pfizer Stock Hand Over Fist. Should You Follow Their Lead?
Pfizer stock lost nearly half its value over the past couple of years, but some of the world's most successful investors bought millions of shares in the first quarter. 
Via The Motley Fool
Time to Pounce: 2 Ultra-High-Yield S&P 500 Dividend Stocks That Are Screaming Buys Right Now
More than a dozen S&P 500 components sport "ultra-high yields." Two of these time-tested titans are begging to be bought by income seekers right now. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Large Cap Biopharmaceuticals Performance
The biotech sector remains a laggard YTD as can be seen by the IBB​​​​​​​. 
Via Talk Markets
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to cancer treatment. 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
3 Blue-Chip Stocks Set to Triple Soon
Blue-chip stocks are great additions to a portfolio. If you're looking for consistent returns, check out these blue-chip stocks to buy. 
Via InvestorPlace
Cómo esta estrella del béisbol toma la iniciativa cuando se trata de neumonía neumocócica
(BPT) - El jugador profesional de béisbol JD Martínez presenta un mayor riesgo de neumonía neumocócica porque tiene asma y no quiere dejar que eso decida si va a seguir jugando, o no. Por si no está... 
Via Brandpoint
3 High-Yield Dividend Stocks I'm Buying Hand Over Fist
There's a lot to like with these great stocks. 
Via The Motley Fool
3 Reliable Dividend Stocks With Yields Above 5% You Can Buy With Less Than $100 Right Now
High yields and a strong chance for steady payout raises in the years ahead make these great stocks to buy now. 
Via The Motley Fool
Billionaires Are Buying These High-Yield Dividend Stocks Left and Right. Should You Follow Their Lead?
Billionaire money managers have bought millions of shares of both Pfizer and Walgreens Boots Alliance this year. 
Via The Motley Fool
Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). 
Via Benzinga
Topics Cannabis
Exposures Cannabis
European Patent Office Sides with Moderna In COVID-19 Vaccine Patent Dispute With Pfizer/BioNTech
Moderna wins a crucial legal battle at the European Patent Office against Pfizer and BioNTech over Covid-19 vaccine patents. 
Via Benzinga
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
GSK Completely Exits Sensodyne Toothpaste Maker Haleon In $1.6B Sale
GSK is fully exiting its position and will no longer hold any ordinary shares in Haleon, maker of Sensodyne toothpaste and Advil painkillers. 
Via Benzinga
7 Value Stocks to Buy and Hold for a Decade of Dominance
Discover the enduring value of seven key value stocks to buy and hold in diverse sectors, presenting unparalleled opportunities. 
Via InvestorPlace
Could Novavax Become the Next Moderna?
Sanofi believes in Novavax's vaccine strengths... 
Via The Motley Fool
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
It depends on what your goals, objectives, and risk tolerances are. 
Via Talk Markets
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.